This advisory summarizes data on the use of sublingual and transmucosal buprenorphine for the medication-assisted treatment of opioid use disorder.

This advisory answers questions about the seriousness of prescription drug misuse. It explains how people become dependent on prescription drugs, and treatment options. The advisory also offers necessary treatment resources for professionals.

This advisory defines protracted withdrawal and identifies specific withdrawal symptoms associated with alcohol, opioids, methamphetamine, cocaine, marijuana, and benzodiazepines. The advisory also explains how protracted withdrawal differs from acute withdrawal, and gives tips to help clients manage it in recovery.